Our recombinant SARS-CoV-2 antigens find application in research, diagnostics or can even be tested as a vaccine. myBIOS also focuses on product applications, i.e. the development of novel strategies for antibody testing. We are aiming for an antibody test made of Pichia produced components only. Currently, we are evaluating protein-HRP conjugates.